In Depth 3 Sep 2025 How are biotechs tackling malaria? As a recent approval closes a major therapeutic gap, let’s take a look at some of the latest progress and new treatments against malaria. September 3, 2025 - 13 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Webinars 25 Aug 2025Advancements in antimalarial drug discovery and development Explore innovations in antimalarial drug discovery, from screening and compound design to resistance mechanisms and PK optimization. August 25, 2025 Share WhatsApp Twitter Linkedin Email
Podcast 29 Nov 2024Can biotech beat mosquito-borne diseases? With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes. November 29, 2024 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
News and Trends 17 Apr 2023 Ghana becomes first country to approve University of Oxford malaria vaccine Ghana has granted full national licensure for the University of Oxford’s R21/Matrix-M malaria vaccine, marking the first regulatory clearance for the vaccine for use in any country. Developed by the University of Oxford, leveraging Novavax’s adjuvant technology, and manufactured and scaled up by the Serum Institute of India PvT Ltd (SIIPL), the vaccine has been […] April 17, 2023 - 4 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Sep 2022 Fight against malaria boosted by findings from a vaccine trial showing high efficacy Hope that malaria could be eradicated forever has been given a boost after new findings from a vaccine trial showed a high-rate of efficacy. Researchers from the University of Oxford and their partners have yesterday (September 8) reported new findings from their malaria vaccine R21/Matrix-M phase 2b trials following the administration of a booster dose. […] September 9, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Manus Bio receives additional funding to fight malaria with biotech U.S. biomanufacturer Manus Bio has received a fourth award from the Bill & Melinda Gates Foundation to develop a scalable production route for the potential antimalarial drug, artemisinin. The $2 million award will enable Manus Bio to begin scaling up the biological process it has developed towards the chemical intermediate, dihydroartemisinic acid. Economical and scalable […] September 2, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Aug 2022 KU Leuven spin-off AstriVax raises €30M for vaccine platform – first stop, yellow fever A Belgian university spinoff has generated the biggest seed capital financing in the institution’s history. Closing with €30 million ($30 million), AstriVax will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various […] August 25, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 2 Aug 2022 The evolving arsenal against mosquito-borne diseases Genetic engineering is breaking new ground in the control of mosquito-borne diseases. However, a genetic engineering approach isn’t the only option, as many biotech companies aim to prove. As the global climate continues to warm, disease-spreading mosquitoes such as Aedes aegypti are expected to establish themselves in the U.S. and Europe. This could result in […] August 2, 2022 - 8 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 Companies come together in fight against Dengue Fever A vaccine to treat dengue fever, the mosquito-borne disease, is the end goal of two companies who have signed an agreement to produce and commercialize a lead candidate in the fight against the disease. Emergex Vaccines Holding Limited, a clinical-stage biotech company, recently announced that it has agreed a collaboration with the Molecular Biology Institute […] July 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Covid and malaria vaccines on track for mass production in Rwanda Construction of the first African messenger RNA (mRNA) manufacturing facility has started in Africa. This means Biopharmaceutical New Technologies (BioNTech) SE is a step closer to producing mRNA vaccines that teach human cells how to make a protein that will trigger an immune response inside the body. The company is a next generation immunotherapy company […] June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email